Not yet recruitingPhase NA

The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance.

Lead sponsor

Bispebjerg Hospital

Asset

Avexitide

Listed sites

Recruiting sites

Estimated enrollment

Study population

Chronic kidney disease

Eligibility highlights

•Male

Primary endpoint

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06872060

Org study IDH-24012271

Timeline

Milestones

Study first posted2025-03-12actual

Last update posted2025-10-03actual

Study start2026-06-01estimated

Primary completion2027-11-01estimated

Study completion2027-11-01estimated

Assets

Investigational agents

Avexitide

Who this study enrolls

Chronic kidney disease

Who can enroll

Minimum age20 Years

Maximum age60 Years

SexMale

Healthy volunteersAccepted

Inclusion criteria

•Normal health confirmed through; Interview and Medical examination

•Normal values with respect to blood concentrations of fasting plasma glucose, fasting plasma total cholesterol, fasting triglycerides, HDL, LDL, creatinine, liver function tests, and electrolytes

•Informed consent

Exclusion criteria

•Immunosuppressive treatment in the previous 12 months

•Alcohol abuse

•Medical treatment with oral glucocorticoids, dipeptidyl peptidase-4 (DPP-4) inhibitors, or GLP-1 receptor agonists, which, in the opinion of the principal investigator, may interfere with glucose metabolism

•Use of lithium

•Medical treatment that affects insulin secretion or the renin-angiotensin-aldosterone system

•Liver disease (ALT > 2x normal value)

•Renal impairment (serum creatinine > 130 µM and/or albuminuria)

•Individuals with severe claustrophobia

•Individuals with MR-incompatible foreign bodies

•Individuals with hypertension

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.